Infectious Diseases Department, Hospital Carlos III, Madrid, Spain.
J Med Virol. 2013 Feb;85(2):200-9. doi: 10.1002/jmv.23447. Epub 2012 Nov 21.
Double negative (DN) T cells are CD3(+), CD4(-), CD8(-) cells with either T-cell receptors (TCR) αβ or TCR γδ whose importance on protection against HIV infection is unknown. Since HIV-exposed seronegative individuals correspond to an ideal group in whom correlates of protection are expected, the role of these cells was studied in 13 HIV-serodiscordant couples in a stable relationship and reporting unprotected sexual intercourses. HIV-specific immune responses mediated by DN T-cells were evaluated by measuring intracellular IFNγ and MIP1β (CCL4) production in response to HIV-Gag peptides. Thirty-five healthy controls not exposed to HIV were tested similarly and used to define a threshold for positive responses. Interestingly, Gag-specific DN T-cell responses were found in 3/13 (23%) HIV-exposed seronegative individuals (Group A), involving both DN/αβ(+) and DN/γδ(+) T-cells through MIP1β and IFNγ production. 4/13 (30%) of partners infected with HIV (Group B) also showed Gag-specific responses but were mediated exclusively by DN/γδ(+) T-cells, mainly through IFNγ production. DN T-cells in Group A individuals can display differential HIV-specific immune responses, which might contribute to the low susceptibility to infection with HIV shown by individuals in Group A.
双阴性 (DN) T 细胞是 CD3(+)、CD4(-)、CD8(-)细胞,其 T 细胞受体 (TCR) 要么为αβ,要么为 TCR γδ,其在预防 HIV 感染方面的重要性尚不清楚。由于 HIV 暴露但血清阴性的个体对应于一个理想的群体,预计在该群体中会出现保护相关因素,因此研究了这些细胞在 13 对稳定关系且报告有未受保护的性接触的 HIV 血清不一致的夫妇中的作用。通过测量 HIV-Gag 肽刺激后 IFNγ 和 MIP1β(CCL4)的细胞内产生来评估由 DN T 细胞介导的 HIV 特异性免疫应答。对 35 名未接触过 HIV 的健康对照者进行了类似的测试,并用于定义阳性反应的阈值。有趣的是,在 3/13(23%)的 HIV 暴露但血清阴性的个体(A 组)中发现了 Gag 特异性 DN T 细胞应答,涉及通过 MIP1β 和 IFNγ 产生的 DN/αβ(+)和 DN/γδ(+)T 细胞。13 名感染 HIV 的伴侣中有 4/13(30%)(B 组)也显示了 Gag 特异性反应,但仅由 DN/γδ(+)T 细胞介导,主要通过 IFNγ 产生。A 组个体中的 DN T 细胞可以显示出不同的 HIV 特异性免疫应答,这可能有助于 A 组个体对 HIV 感染的低易感性。
Chin Med J (Engl). 2006-10-5
Signal Transduct Target Ther. 2023-11-22
Front Pediatr. 2020-10-19
J Virol. 2020-11-23
Cell Mol Immunol. 2021-1
J Acquir Immune Defic Syndr. 2016-6-1